The piggyBac™ Transposon System
Transposagen is the worldwide exclusive licensee of the piggyBac transposon system for most fields of use including research, therapeutics and bioproduction. Currently, Transposagen is in close collaboration with different groups around the world who are utilizing the system to develop therapeutics.
The piggyBac genome engineering technology has applications in immunotherapy, stem cells and gene therapy. Recently the piggyBac system has shown therapeutic promise in preclinical studies for several areas of disease including cancer immunotherapy.
Molecular Therapy (2011) PiggyBac Modified EBV-specific T Cells for HER2 Cancer
Other technologies have recently shown clinical promise in humans for similar treatment: NEJM 2011 Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
Transposagen’s piggyBac technology may have advantages over competing technologies as it is a safe non-viral system with a much larger DNA cargo capacity. Please see our brochure for more detailed information: TGEN piggyBac Immunotherapy brochure.
Groups that Transposagen is collaborating with for cancer immunotherapy development
Dr. Kenneth Micklethwaite
Clinical Lecturer
Medicine, Westmead Clinical School
Westmead Millennium Institute for Medical ResearchC24 – Westmead Hospital
The University of Sydney
NSW 2006 Australia
Dr. Micklethwaite is performing preclinical studies with a goal of producing protocols for use in a clinical trial and has recently presented a poster entitled Generation of T-cells Expressing a CD19-Specific Chimeric Antigen Receptor Using the PiggyBac Transposon/Transposase Gene Modification System at the annual Haematology Society of Australia and New Zealand conference.
TGEN001: Transposagen’s Visceral Pain Compound
The transient receptor potential (TRP) cation channel superfamily members are noted for their ability to activate nociceptive nerve endings, specialized for transmission of pain (Caterina et al., 2000; Caterina and Julius, 2001). At least one potential pain therapeutic targeting a Trp family member, Trpv1, has entered clinical trials (Xia et al. Transient Receptor Potential Channels (2011) 704, 637-665).
In collaboration with University of Kentucky researcher Dr. Karin High, Transposagen discovered Trpc4 as a target for pain through characterization of the Trpc4 TKO® Knockout Rat: Trpc4 Pain Brochure.
Transposagen has a patent portfolio covering the Trpc4 rat model of pain, Trpc4 as a target for pain therapeutics and a variety of antagonists against Trpc4, including our lead candidate and its derivatives. Please contact us for partnering opportunities.